| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ... Nature cell biology 23 (9), 1023-1034, 2021 | 86 | 2021 |
| ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer S Nouruzi, D Ganguli, N Tabrizian, M Kobelev, O Sivak, T Namekawa, ... Nature Communications 13 (1), 2282, 2022 | 50 | 2022 |
| Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer D Thaper, S Vahid, R Kaur, S Kumar, S Nouruzi, JL Bishop, M Johansson, ... Scientific reports 8 (1), 17307, 2018 | 35 | 2018 |
| First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer. DL Thaper, R Munuganti, S Nouruzi, S Kumar, S Kim, S Vahid, O Sivak, ... Journal of Clinical Oncology 37 (7_suppl), 260-260, 2019 | 3 | 2019 |
| ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer N Tabrizian, S Nouruzi, CJ Cui, M Kobelev, T Namekawa, I Lodhia, ... Cell Reports 42 (8), 2023 | 1 | 2023 |
| Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer S Nouruzi, N Tabrizian, A Zoubeidi Endocrinology 164 (4), bqad023, 2023 | 1 | 2023 |
| ASCL1 activates neuronal stem cell-like lineage programming through the remodeling of the chromatin landscape in prostate cancer S Nouruzi, D Ganguli, N Tabrizian, M Kobelev, O Sivak, T Namekawa, ... Cancer Research 83 (7_Supplement), 4730-4730, 2023 | | 2023 |
| The role of the lineage oncogene ASCL1 in treatment-induced neuroendocrine prostate cancer S Nouruzi University of British Columbia, 2022 | | 2022 |
| Selective inhibition of transcription factor BRN2 as a treatment strategy for Small Cell Prostate Cancer D Thaper, R Munuganti, A Aguda, S Kim, S Ku, S Kumar, S Vahid, ... Cancer Research 80 (16_Supplement), 3083-3083, 2020 | | 2020 |
